Antiviral therapy of hepatitis C--present and future (Q40915885)

24 September 2017

1 reference

title

Antiviral therapy of hepatitis C--present and future (English)

1 reference

24 September 2017

Hoofnagle JH

1

1 reference

24 September 2017

Di Bisceglie AM

series ordinal

2

1 reference

24 September 2017

Shindo M

series ordinal

3

1 reference

24 September 2017

1 January 1993

1 reference

24 September 2017

Journal of Hepatology

1 reference

24 September 2017

17 Suppl 3

1 reference

24 September 2017

S130-6

1 reference

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

24 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Randomised controlled trial of interferon alfa (lymphoblastoid interferon) in chronic non-A non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

A randomized controlled trial of interferon alfa-2b as therapy for chronic non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

One-year treatment of chronic non-A, non-B hepatitis with interferon alfa-2b

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Therapy of chronic post-transfusion non-A, non-B hepatitis with interferon alfa-2b: Swedish experience

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Prolonged treatment (18 months) of chronic hepatitis C with recombinant alpha-interferon in comparison with a control group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Recombinant human interferon alfa-2a in community-acquired non-A, non-B chronic active hepatitis. Preliminary results of a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Decrease in Serum Hepatitis C Viral RNA during Alpha-Interferon Therapy for Chronic Hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Detection of hepatitis C viral sequences in non-A, non-B hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

A long-term study of hepatitis C virus replication in non-A, non-B hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Autoimmune chronic hepatitis exacerbated by alpha-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Recurrence of hepatitis C virus infection after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Transmission of hepatitis C virus by organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Resolution of acute hepatitis C after therapy with natural beta interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Biochemistry and clinical applications of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2805%2980438-6

7 January 2021

10.1016/S0168-8278(05)80438-6

Identifiers

DOI

1 reference

release_7xm65zqvo5egrkhzqh7j7lovby

24 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7xm65zqvo5egrkhzqh7j7lovby

24 November 2022

mapped directly with Wikidata item

1 reference